IRVINE, Calif., Jan. 24, 2022 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced changes to its Board of Directors. Paul W. Hoelscher, Executive Vice President, Chief Financial Officer of Horizon Therapeutics plc, has been appointed… Continue reading Reneo Pharmaceuticals Announces Changes to its Board of Directors
